Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulla Puistola

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|October 22, 2015
[Cancer in an elderly woman]Peeter Karihtala, Ulla Puistola
Duodecim; Laaketieteellinen Aikakauskirja|November 6, 2013
[Treatment strategies in ovarian cancer]Ulla Puistola, Arto Leminen
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2010
[Abdominal infection unresponsive from antibiotic therapy in middle-aged woman]Vesa Koivukangas, Ulla Puistola
Duodecim; Laaketieteellinen Aikakauskirja|May 24, 2012
[Cancer diagnosed during pregnancy]Erja Halmesmäki, Ulla Puistola
Anticancer Research|January 12, 2007
The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancerMarita Rauvala, Taina Turpeenniemi-Hujanen, Ulla Puistola
BMC Cancer|July 3, 2015
Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancerMarjo Pylväs-Eerola, Peeter Karihtala, Ulla Puistola
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 27, 2019
Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetesElina Urpilainen, Jenni Kangaskokko, Ulla Puistola, et al.
Annals of Translational Medicine|January 25, 2021
Metformin and ovarian cancer: the evidenceElina Urpilainen, Ulla Puistola, Stergios Boussios, et al.
Fertility and Sterility|May 1, 2010
Distinctively low levels of serum 8-hydroxydeoxyguanosine in women with polycystic ovary syndromeHenri Sova, Laure Morin-Papunen, Ulla Puistola, et al.
Anticancer Research|April 16, 2010
Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trialPeeter Karihtala, Johanna Mäenpää, Taina Turpeenniemi-Hujanen, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Duodecim; Laaketieteellinen Aikakauskirja|October 22, 2015
[Cancer in an elderly woman]Peeter Karihtala, Ulla Puistola
Duodecim; Laaketieteellinen Aikakauskirja|November 6, 2013
[Treatment strategies in ovarian cancer]Ulla Puistola, Arto Leminen
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2010
[Abdominal infection unresponsive from antibiotic therapy in middle-aged woman]Vesa Koivukangas, Ulla Puistola
Duodecim; Laaketieteellinen Aikakauskirja|May 24, 2012
[Cancer diagnosed during pregnancy]Erja Halmesmäki, Ulla Puistola
Anticancer Research|January 12, 2007
The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancerMarita Rauvala, Taina Turpeenniemi-Hujanen, Ulla Puistola
BMC Cancer|July 3, 2015
Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancerMarjo Pylväs-Eerola, Peeter Karihtala, Ulla Puistola
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 27, 2019
Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetesElina Urpilainen, Jenni Kangaskokko, Ulla Puistola, et al.
Annals of Translational Medicine|January 25, 2021
Metformin and ovarian cancer: the evidenceElina Urpilainen, Ulla Puistola, Stergios Boussios, et al.
Fertility and Sterility|May 1, 2010
Distinctively low levels of serum 8-hydroxydeoxyguanosine in women with polycystic ovary syndromeHenri Sova, Laure Morin-Papunen, Ulla Puistola, et al.
Anticancer Research|April 16, 2010
Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trialPeeter Karihtala, Johanna Mäenpää, Taina Turpeenniemi-Hujanen, et al.
Pageof 7